Marksans Pharma strengthens European presence with €7.5 million QliniQ acquisition - CNBC TV18
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Ligand Pharmaceuticals has completed the acquisition of XOMA Royalty Holdings, a healthcare services other business in California, for $39.00. XOMA Royalty Holdings holds royalty interests tied to healthcare assets, and Ligand Pharmaceuticals acquisitions focus on strengthening its pipeline economics through healthcare M&A. The Ligand Pharmaceuticals acquisitions add CA acquisitions exposure to royalty-based revenue streams in Emeryville, California. The merger acquisition is an announced strategic acquisition by a strategic buyer, with deal size undisclosed and deal terms filed in an SEC S-4 registration statement, subject to completion after regulatory and shareholder approvals.
Marksans Pharma→Teva Pharmaceuticals Ireland and Teva Pharmaceuticals Canada
Jun 1, 2026
Marksans Pharma→QliniQ
Jun 1, 2026
Frazier Healthcare Partners→Altruix
May 31, 2026
Signos
May 31, 2026
Sterling Bay→Pacific Center
May 29, 2026